Skip to main content
Fig. 3 | Journal of Nanobiotechnology

Fig. 3

From: Cancer cell-specific and pro-apoptotic SMAC peptide-doxorubicin conjugated prodrug encapsulated aposomes for synergistic cancer immunotherapy

Fig. 3

Immunogenic cell death (ICD) of Aposomes in cell culture system. a Fluorescence images CRT-stained CT26 cells after treated with free DOX, DOXIL or Aposomes (2 µM based on DOX contents) for 48 h. b Relative amount of HMGB1 and ATP released from CT26 cells treated with free DOX, DOXIL or Aposomes (2 µM based on DOX contents) for 48 h. c Fluorescence images of CellTracker Green-labeled BMDMs co-cultured with free DOX-, DOXIL- or Aposome-treated CT26 cells (pHrodo labeled) for 2 h. d Percentage of mature DCs (CD11c+CD40+CD86+) and e cytotoxic T cells (CD45+CD3+CD8+) within the lymphocytes after co-culture with CT26 cells treated with free free DOX, DOXIL or Aposomes for 48 h. f Relative amount of TNF-α, IFN-γ and IL-17 in the cell culture medium after co-culture of lymphocytes with CT26 cells treated with free free DOX, DOXIL or Aposomes for 48 h. Significance was determined by Tukey − Kramer post-hoc test

Back to article page